Protocol Ledger

FDAAA 801 Governance & Registry Hygiene · Empirical Biostatistics Study

FDAAA 801 Results Reporting Lags and Primary Outcome Amendments in Industry vs Academic Sponsored Trials

Auditing 55,377 raw clinicaltrials.gov Phase II and Phase III records alongside fda.gov approval archives uncovers stark compliance divergence between biopharma and academic sponsors: 8,352 protocols sit in stale UNKNOWN status past completion windows, 487 carry future placeholder start dates, and 40 industry sponsors anonymize 155,062 investigative site slots.

Published: 2026-11-18 Publication ID: 47c4426df7e9d67d5bfe Primary Sources: clinicaltrials.gov & fda.gov

Statutory Mechanics of FDAAA Section 801 and 42 CFR Part 11

Under Section 801 of the Food and Drug Administration Amendments Act of 2007 (FDAAA 801, 42 U.S.C. Section 282(j)) and the HHS/NIH Final Rule (42 CFR Part 11, effective January 2017), responsible parties conducting Applicable Clinical Trials (ACTs) of FDA-regulated drug, biologic, and device interventions must register prospective primary and secondary outcome measures within 21 days of first patient enrollment and submit structured summary clinical results no later than 12 months after the Primary Completion Date (unless a statutory certification for delayed submission pending initial FDA approval is filed).

In empirical registry audits, however, evaluating FDAAA 801 timeliness and outcome integrity requires looking upstream of the results module itself. When a sponsor fails to verify a record for more than two years after its registered completion date passed, NLM automatically transitions the study's status to UNKNOWN. Across our reconciled 2018 to 2026 Phase II/III universe, 8,352 protocols (15.22% of the entire 54,890 cohort) sit in unverified UNKNOWN status, creating an immediate blind spot for systematic reviewers and meta-analysts tracking unpublished negative trials.

Table 1. ClinicalTrials.gov v2 Registry Hygiene, Date-Horizon Anomalies, and Disclosure Audit Counts
Registry Audit & Quarantine Dimension Verified Count FDAAA 801 & Epidemiological Audit Implication
Raw API v2 Phase II/III Interventional Protocols 55,377 Full upstream NLM extraction before temporal and outlier quarantine
Future or Placeholder Start Dates Excluded (>2026) 487 Protocols posting placeholder 2027 to 2050 start dates excluded from cohort
Stale Unverified UNKNOWN Status Protocols 8,352 Unverified for 24+ months past registered completion date; masks quiet abandonments
Far-Future Completion Horizons (>2040 Quarantined) 56 Placeholder dates (up to 2050-03) defer automated primary-completion clocks
Anticipated vs Actual Enrollment Down-Sizing 80.0 vs 71.0 Cohort-wide median actual enrollment trails target sample size by 11.25%
Anonymized CRO Site Masking Slots (40 Sponsors) 155,062 (16.34%) Masks physical hospital identities behind generic "Research Site" labels

Industry vs Academic/Federal Sponsors: Two Distinct Governance Failure Modes

Cross-tabulating consolidated biopharma corporations against major academic cancer centers and federal institutes in Table 2 exposes an asymmetric governance pattern rather than uniform compliance by either sector:

  • Academic & Cooperative Group Protocols Suffer Timeline Drift, Sample Down-Sizing, and Reporting Lags: Investigator-initiated and cooperative-group Phase II studies at flagship academic institutions maintain exemplary 100.0% physical site transparency, yet experience severe sample-size shrinkage and multi-year completion extensions that routinely accompany primary outcome amendments (converting underpowered survival or clinical response endpoints into exploratory biomarker readouts). For example, NCI-sponsored trials enroll a median of 22.5 actual patients against a 90.0 target over 1,725.5 median days (62.86% closed stop rate), MD Anderson sponsor-led protocols enroll 24.0 vs 40.0 target over 1,707.5 days (78.29% closed stop rate), and MSKCC sponsor-led protocols run 1,828.5 median days.
  • Large Biopharma Enforces Tighter FDAAA Timelines, Yet 40 Commercial Sponsors Mask Hospital Sites: Commercial registration sponsors deploy dedicated regulatory operations teams to police FDAAA Section 801 12-month results clocks and FDA Pre-NDA statistical analysis plans (SAPs), achieving much tighter completion durations (Pfizer 607 days, Novo Nordisk 666 days, Eli Lilly 691 days, GSK 700 days). However, while Merck (99.9%), Pfizer (99.9%), Roche/Genentech (99.9%), and Eli Lilly (100.0%) name virtually every hospital site, other global sponsors obscure site-level auditability by registering anonymized CRO site codes: AstraZeneca discloses just 0.9% of its facility slots (54,582 masked slots), GSK discloses 3.8% (15,154 masked slots), Novartis discloses 22.0% (20,338 masked slots), and Sanofi discloses 27.3% (14,134 masked slots).
Table 2. Biopharma Industry vs Academic/NIH Sponsor Execution, Enrollment Realization, and Site Disclosure Matrix
Consolidated Lead Sponsor Sector Trials Closed Stop % Actual / Target N Median Days Site Discl. % NDA/BLA (18-26)
AstraZeneca Biopharma Industry 534 25.2% 181.0 / 334.0 782 0.9% 21
Novartis Biopharma Industry 492 38.0% 119.0 / 180.0 1,033 22.0% 29
Merck & Co. Biopharma Industry 439 18.1% 301.5 / 352.0 1,135 99.9% 15
Pfizer Biopharma Industry 377 31.2% 241.0 / 492.0 607 99.9% 34
Roche / Genentech Biopharma Industry 353 32.5% 185.5 / 292.5 1,185 99.9% 19
Eli Lilly and Company Biopharma Industry 334 17.0% 312.0 / 462.5 691 100.0% 16
Sanofi Biopharma Industry 328 32.4% 222.5 / 182.5 706 27.3% 11
GSK Biopharma Industry 304 26.1% 284.0 / 363.0 700 3.8% 13
MD Anderson Cancer Center Academic 519 78.3% 24.0 / 40.0 1,708 100.0% 0
National Cancer Institute (NCI) Federal / NIH 458 62.9% 22.5 / 90.0 1,726 100.0% 0
Memorial Sloan Kettering Cancer Center Academic 308 38.9% 24.0 / 54.0 1,829 100.0% 0
Mayo Clinic Academic 253 39.3% 27.0 / 60.0 998 100.0% 0
Johns Hopkins University Academic 193 34.4% 33.0 / 49.0 1,527 100.0% 0
Stanford University Academic 139 43.5% 30.0 / 48.0 743 100.0% 0

How Endpoint Amendments Interact With Enrollment Down-Sizing

When a randomized Phase II or Phase III study falls 40% to 75% short of its registered target sample size, statistical power for its original time-to-event or clinical composite primary outcome collapses unless event rates substantially exceed protocol assumptions. In clinical due diligence, a wide gap between historical EnrollmentCount (Estimated) and final EnrollmentCount (Actual) paired with repeated Primary Completion Date extensions is the strongest quantitative indicator to inspect the study's archive history on ClinicalTrials.gov for mid-study primary-to-secondary endpoint swaps or post-hoc subgroup redefinitions. FDA Notices of Noncompliance issued under FDAAA 801 and NIH grant-withholding enforcement policies have sharply increased regulatory scrutiny on overdue academic and mid-cap biotech sponsors alike, making clean registry date and outcome governance a direct prerequisite for partnership readiness.

Methodology and Audit Scope Notes

Readers can inspect exact quarantine samples (including NCT identifiers for future start dates and multi-decade completion horizons) inside the Data Provenance & Quarantine Audit tab. Note that non-U.S. single-country trials without an FDA IND or U.S. manufacturing nexus voluntarily register on ClinicalTrials.gov to satisfy ICMJE medical journal publication rules rather than statutory FDAAA 801 jurisdiction.